BioStar Capital
Venture Capital
Active
Charlevoix, United States
47
25M
29
2.24
4
0.38
9
- Stages of investment
- Areas of investment
Summary
BioStar Ventures appeared to be the VC, which was created in 2003. The company was established in North America in United States. The main department of described VC is located in the Petoskey.
The standard case for the fund is to invest in rounds with 4-5 partakers. Despite the BioStar Ventures, startups are often financed by Safeguard Scientifics, Pontifax, Menlo Ventures. The meaningful sponsors for the fund in investment in the same round are Triventures, Safeguard Scientifics, MedFocus Fund. In the next rounds fund is usually obtained by Safeguard Scientifics, HealthQuest Capital, HBM Healthcare Investments AG.
The current fund was established by Louis Cannon. We also calculated 5 valuable employees in our database.
Opposing the other organizations, this BioStar Ventures works on 7 percentage points less the average amount of lead investments. The usual things for fund are deals in the range of 10 - 50 millions dollars. The fund is generally included in 2-6 deals every year. When the investment is from BioStar Ventures the average startup value is 10-50 millions dollars. Speaking about the real fund results, this VC is 2 percentage points more often commits exit comparing to other organizations. The high activity for fund was in 2014. Despite it in 2019 the fund had an activity. The increased amount of exits for fund were in 2014.
Moreover, a startup needs to be at the age of 6-10 years to get the investment from the fund. For fund there is a match between the country of its foundation and the country of its the most frequent investments - United States. We can highlight the next thriving fund investment areas, such as Robotics, Medical Device. Among the various public portfolio startups of the fund, we may underline Corindus, SynergEyes, Domain Surgical The fund has exact preference in a number of founders of portfolio startups.
Investor highlights
- Industry focus
Discover reliable insights
Find relevant VC investors, identify key contacts and secure funding opportunities.
Investments analytics
Last fund
- Fund size
- USD 130300000
- Fund raised date
- 2023-12-06
Analytics
- Total investments
- 47
- Lead investments
- 4
- Exits
- 9
- Rounds per year
- 2.24
- Follow on index
- 0.38
- Investments by industry
- Medical Device (40)
- Health Care (38)
- Medical (23)
- Biotechnology (14)
- Manufacturing (9) Show 11 more
- Investments by region
-
- United States (41)
- Italy (2)
- Israel (3)
- South Korea (1)
- Peak activity year
- 2014
- Number of Unicorns
- 1
- Number of Decacorns
- 1
Discover reliable insights
Leverage validated data, identify key contacts and secure funding opportunities for your business.Quantitative data
- Avg. startup age at the time of investment
- 15
- Avg. valuation at time of investment
- 54M
- Group Appearance index
- 0.83
- Avg. company exit year
- 9
- Avg. multiplicator
- 4.38
- Strategy success index
- 0.50
Need more data?
Get access to full data about investors, including their team, contact information, and historic data.
Latest deals
Company name | Deal date | Industry | Deal stage | Deal size | Location |
---|---|---|---|---|---|
Ablative Solutions | 19 Jun 2012 | Biotechnology, Health Care, Medical Device | Early Stage Venture | 5M | United States, California, San Jose |
Ceyentra Technologies | 27 Nov 2018 | Information Technology, Machine Learning, Mobile Apps, Marketing, Consulting | Early Stage Venture | 75K | Western Province, Western, Sri Lanka |
Eyeview | 01 Mar 2010 | Video, Advertising, Brand Marketing, Video Advertising | Early Stage Venture | 6M | United States, New York, New York |
MMI | 21 Feb 2024 | Health Care, Robotics, Medical Device, Medical | Late Stage Venture | 110M | Tuscany, Italy, Italy |
Similar funds
By same location
By same geo focus
By doing lead investments
At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).
Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.